| COVID-19 |
1 |
1 |
| Clinical Guidelines |
0 |
0.74 |
| Pregnancy |
0 |
0.57 |
| Biologic Therapy |
0 |
0.34 |
| Antiviral Agents |
0 |
0.25 |
| Corticosteroids |
0 |
0.25 |
| Immunization |
0 |
0.25 |
| Monoclonal Antibody |
0 |
0.25 |
| Plasma |
0 |
0.25 |
| Influenza |
0 |
0.2 |
| Antihistamine |
0 |
0.12 |
| Cancer |
0 |
0.12 |
| Comparative Effectiveness |
0 |
0.12 |
| Drug Interaction |
0 |
0.12 |
| Immunocompromise |
0 |
0.12 |
| New York |
0 |
0.12 |
| Oregon |
0 |
0.12 |
| Selective Serotonin-Reuptake Inhibitors |
0 |
0.12 |
| Socioeconomics |
0 |
0.12 |
| Antibiotics |
0 |
0.09 |
| Neuroendocrine Tumor |
0 |
0.09 |
| Social Determinants of Health |
0 |
0.09 |